Table 1.
Clinical data of 90 patients
| Characteristics | Total | Stage I | Stage II | Stages III + IV | P-value |
|---|---|---|---|---|---|
| Number of patients | 90 | 24 | 21 | 45 | |
| Median age (year) | 62 | 62 | 63 | 63 | 0.237 |
| Gender | 0.315 | ||||
| M | 51 | 12 | 15 | 24 | |
| F | 39 | 12 | 6 | 21 | |
| Tumor site | 0.168 | ||||
| Left lung | 41 | 12 | 9 | 30 | |
| Right lung | 49 | 12 | 12 | 15 | |
| Diameter of tumor | 0.373 | ||||
| ≥5 cm | 21 | 0 | 6 | 15 | |
| <5 cm | 69 | 24 | 15 | 30 | |
| Degree of differentiation | 0.412 | ||||
| High + medium | 50 | 17 | 7 | 26 | |
| Low | 40 | 7 | 14 | 19 | |
| EGFR state | 0.097 | ||||
| M+ | 62 | 18 | 12 | 32 | |
| M− | 28 | 6 | 9 | 13 | |
| Smoking history | 0.401 | ||||
| Yes | 36 | 6 | 9 | 21 | |
| No | 54 | 18 | 12 | 24 | |
| CEA | 3.95 (2.29–12.65) | 2.58 (1.36–3.47) | 4.24 (1.99–9.67) | 5.37 (3.00–26.07) | 0.049 |
| CYFRA21-1 | 2.30 (1.90–3.50) | 1.90 (1.60–2.20) | 2.35 (2.00–3.30) | 2.50 (1.90–3.70) | 0.237 |
| CA125 | 9.10 (3.40–18.30) | 5.30 (3.80–11.05) | 9.50 (4.30–16.40) | 9.10 (2.30–21.00) | 0.567 |
Abbreviations: CA125, cancer antigen 125; CEA, carcino-embryonic antigen; CYFRA21-1, cytokeratins 21-1; EFGR, epidermal growth factor receptor.